BioNTech SE (BNTX) Reports Q1 EPS of EUR4.39
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BioNTech Announces First Quarter 2021 Financial Results and Corporate Update
May 10, 2021 7:00 AM EDTMore than 450 million doses of BNT162b2 supplied to 91 countries or territories worldwide as of May 6, 2021Signed agreements for over 1.8 billion doses of BNT162b2 in 2021 and first contracts signed for periods 2022 and beyond Announced planned expansion of global footprint to Asia with establishment of first regional headquarters for south east Asia in Singapore, including a fully-integrated and state-of-the art mRNA manufacturing facility In oncology, a first-in-human Phase 1 trial started for the neoantigen-targeting T cell therapy, BNT221. The development of BioNTechs oncology pipeline has continued to accelerate with 14 product candidates now in 15 ongoing... More
